Special Protocol Assessments Get Special Focus In Antibiotic Guidance
This article was originally published in Pharmaceutical Approvals Monthly
FDA’s final guidance on use of non-inferiority studies to support antibacterial drug approval is little changed from a 2007 draft version, but it provides further clarity for sponsors operating under a special protocol assessment.
You may also be interested in...
Agency makes clear that triglyceride levels are no longer an acceptable surrogate for reducing cardiovascular risk.
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
A fierce dispute between researchers and clinicians who think community-acquired bacterial pneumonia drugs should be evaluated by their effect on mortality, and those who favor symptom-based evaluation, is unlikely to be quelled by actions taken at the Dec. 9 meeting of FDA's Anti-Infective Drugs Advisory Committee, which gave each side some of what it wanted